Akero Therapeutics
Akero Therapeutics (AKRO) reported its Q22025 financial results for the period ending June 30, 2025 as well as providing a business update. The report was published from the 96-Week Phase 2b SYMMETRY trial published in the New England Journal of Medicine.

Three presentations highlighted data demonstrating statistically significant reversal of MASH compensated cirrhosis, and the anti-fibrotic activity . . .